These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 3482992)
1. [Indirubin in the treatment of chronic myelocytic leukemia (CML)--estimation of labelling index of bone marrow cells by 3H-TdR]. You YC; Mi JX; Wan JH; Yang TY; Wang ZC; Qian LS Zhonghua Zhong Liu Za Zhi; 1987 Nov; 9(6):418-20. PubMed ID: 3482992 [TBL] [Abstract][Full Text] [Related]
2. [Sister chromatid exchange frequency of bone marrow cells and its response to indirubin in chronic myeloid leukemia]. Feng BZ Zhonghua Zhong Liu Za Zhi; 1984 Sep; 6(5):357-60. PubMed ID: 6598442 [No Abstract] [Full Text] [Related]
3. [Effect of indirubin on SCE frequencies of BM cells in chronic myeloid leukemia]. Feng BZ; Zhang YH; Qian LS; Chu YL Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1984 Aug; 6(4):308-10. PubMed ID: 6241076 [No Abstract] [Full Text] [Related]
4. Colony growth in cultures from bone marrow and peripheral blood after curative treatment for leukemia and severe aplastic anemia. Betticher DC; Huxol H; Müller R; Speck B; Nissen C Exp Hematol; 1993 Nov; 21(12):1517-21. PubMed ID: 8405233 [TBL] [Abstract][Full Text] [Related]
5. Regulation of bone marrow myeloblast proliferation in chronic myeloid leukemia. Stryckmans P; Debusscher L; Socquet M Cancer Res; 1976 Sep; 36(9 pt.1):3034-8. PubMed ID: 1067897 [TBL] [Abstract][Full Text] [Related]
6. Cytochemical variants of neutrophil leukocyte populations in chronic myelocytic leukaemia. A microspectrophotometric study of the change in the periodic acid-Schiff (PAS) reaction in blood and bone marrow neutrophils during busulfan treatment. Gahrton G; Brandt L; Franzén S; Nordén A Scand J Haematol; 1969; 6(6):365-72. PubMed ID: 4190430 [No Abstract] [Full Text] [Related]
7. Apoptosis and proliferation (PCNA labelling) in CML--a comparative immunohistological study on bone marrow biopsies following interferon and busulfan therapy. Thiele J; Zirbes TK; Lorenzen J; Kvasnicka HM; Dresbach S; Manich B; Leder LD; Niederle N; Diehl V; Fischer R J Pathol; 1997 Mar; 181(3):316-22. PubMed ID: 9155719 [TBL] [Abstract][Full Text] [Related]
8. In vitro drug sensitivity studies of CFUc in chronic myelocytic leukemia: I. Suicide indices and busulfan sensitivity determinations during the chronic phase. Preisler HD; Kirshner J Exp Hematol; 1983 Aug; 11(7):618-25. PubMed ID: 6576910 [TBL] [Abstract][Full Text] [Related]
9. [Varying course of pancytopenia after busulfan treatment of chronic myelocytic leukemia (CML)]. Krug K; Stenzel L Folia Haematol Int Mag Klin Morphol Blutforsch; 1978; 105(2):181-7. PubMed ID: 79522 [TBL] [Abstract][Full Text] [Related]
10. [High-dose busulfan with subsequent bone marrow transplantation in poor-risk forms of leukemia]. Urban C; Slavc I; Kaulfersch W; Teubl I Wien Klin Wochenschr; 1987 Mar; 99(5):144-9. PubMed ID: 3554777 [TBL] [Abstract][Full Text] [Related]
11. [Lactate dehydrogenase in human leukemia. A clinico-experimental study]. Van Hove WZ Verh K Vlaam Acad Geneeskd Belg; 1972; 34(5-6):587-732. PubMed ID: 4605768 [No Abstract] [Full Text] [Related]
12. [Chronic myelocytic leukemia: apparent "recovery" for over nine years, following therapeutic medullary hypoplasia. A clinical and cytogenetic study]. Mauruce PA; Ferrier S; Alberto P; Freund M Schweiz Med Wochenschr; 1971 Dec; 101(49):1781-2. PubMed ID: 5291101 [No Abstract] [Full Text] [Related]
13. Treatment of 100 cases of chronic myeloid leukemia with Myleran. Pawelski S; Topolska P; Rechowicz K; Krzyzanowska-Wozniakowska Pol Med Sci Hist Bull; 1968 Jul; 11(3):101-4. PubMed ID: 5243952 [No Abstract] [Full Text] [Related]
15. Effects of interferon treatment on the macrophage population in the bone marrow of patients with Ph1+-CML. Thiele J; Kvasnicka HM; Zirbes TK; Baldus SE; Djuren O; Lienhard H; Lorenzen J; Leder LD; Niederle N; Fischer R Hematopathol Mol Hematol; 1996; 10(4):201-12. PubMed ID: 9042663 [TBL] [Abstract][Full Text] [Related]
16. Progress in indirubin treatment of chronic myelocytic leukemia. Ma MZ; Yao BY J Tradit Chin Med; 1983 Sep; 3(3):245-8. PubMed ID: 6355667 [No Abstract] [Full Text] [Related]
17. Relapse in chronic myeloid leukemia after bone marrow transplantation: biomathematical modeling as a new approach to understanding pathogenesis. Vincent PC; Rutzen-Loesevitz L; Tibken B; Heinze B; Hofer EP; Fliedner TM Stem Cells; 1999; 17(1):9-17. PubMed ID: 10215403 [TBL] [Abstract][Full Text] [Related]
18. Estimation of chronic phase duration in Ph-positive chronic myelocytic leukemia treated with busulfan: statistical analysis on Japanese patients. Hashimoto T; Ohtaki M; Ueoka H; Munaka M; Kuramoto A; Kamada N Int J Hematol; 1994 Jul; 60(1):59-69. PubMed ID: 7919239 [TBL] [Abstract][Full Text] [Related]
19. [Studies on the mechanism of indirubin action in the treatment of chronic granulocytic leukemia. II. Effects of indirubin on nucleic acid and protein synthesis in animal transplantable tumor cells and normal proliferating cells in vitro (author's transl)]. Wu GY; Fang FD Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1980 Jun; 2(2):83-7. PubMed ID: 6448713 [No Abstract] [Full Text] [Related]
20. Studies on human preleukaemia. I. Erythroblast and iron kinetics in aregenerative anaemia with hypercellular bone marrow. Hast R; Reizenstein P Scand J Haematol; 1977 Oct; 19(4):347-54. PubMed ID: 918562 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]